跳至主要内容
临床试验/NCT01849081
NCT01849081
撤回
不适用

Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Massachusetts General Hospital1 个研究点 分布在 1 个国家2019年3月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Non-alcoholic Fatty Liver Disease
发起方
Massachusetts General Hospital
试验地点
1
主要终点
Steatosis by MRS
状态
撤回
最后更新
5年前

概览

简要总结

We are doing this research study to evaluate whether continuous positive airway pressure (CPAP), a treatment for sleep apnea, will also help treat fatty liver disease. Sleep apnea is a disease where a person has interruptions in their breathing while they are sleep. This can lead to low oxygen levels in the blood. CPAP is a mask that delivers oxygen at high pressure to the lungs to prevent a decrease in blood oxygen levels. CPAP is a known treatment for sleep apnea.

注册库
clinicaltrials.gov
开始日期
2019年3月
结束日期
2019年3月
最后更新
5年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Principal Investigator
主要研究者

Kathleen E Corey

Instructor in Medicine

Massachusetts General Hospital

入排标准

入选标准

  • Adults 18 years of age or older with a previous liver biopsy showing NASH and at least grade 2 steatosis
  • Obstructive sleep apnea diagnosed by sleep study.

排除标准

  • Other causes of chronic liver disease
  • cirrhosis
  • less than 33% steatosis identified on magnetic resonance spectroscopy (MRS)
  • Alcohol use \>2 units per day for women or \>3 units per day for men
  • Intolerance to or refusal of CPAP therapy
  • overnight desaturation (more than 10% of the sleep time with oxygen desaturation below 85%)
  • underlying sever sleepiness (Epworth scale more than 15)
  • uncontrolled hypertension
  • Severe heart failure (ejection fracture less than 30%)
  • cardiac arrhythmias (atrial fibrillation or history of ventricular tachycardia)

结局指标

主要结局

Steatosis by MRS

时间窗: 12 weeks

Subjects will undergo baseline and 12 week magnetic resonance spectroscopy to assess the impact of CPAP or diet on fatty liver.

研究点 (1)

Loading locations...

相似试验